Trial Profile
Relative Bioavailability of Both BI 1356 and Pioglitazone After Co-administration Compared to the Bioavailability of Multiple Oral Doses of BI 1356 10 mg qd Alone and Pioglitazone 45 mg qd Alone in Healthy Male and Female Volunteers (an Open Label, Randomised, Multiple-dose, Two-way Crossover Study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2014
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary) ; Pioglitazone
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 16 Jul 2014 New trial record